Trial Information

Summary: An Exploratory Evaluation of Fenretinide (4-HPR) (IND #39,812) as a Chemopreventive Agent for Ovarian Carcinoma [GOG0190]

This research study is to learn why some womens ovaries develop cancers and to see if the study drug fenretinide can slow down or stop cancer from developing in the ovary. The study is considered research because fenretinide has not been approved by the United States Food and Drug Administration (FDA).
No Compensation Provided

Patient Inclusion/Exclusion Criteria:

You may be eligible to participate if you
-are 18 years of age or older
-have a normal pelvic exam within 6 weeks of starting the study
-have a family history of ovarian or breast cancer
-meet additional criteria

You are not eligible for this study if you
-have any heart disease
-have received chemotherapy, hormonal therapy, radiotherapy to the pelvis three months before the study starts
-are pregnant or breastfeeding

If you would like to learn more about participating in this study, please send an e-mail message using the form below.